David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Amit Sanyal, MD: A Clinician’s Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Aug

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Amit Sanyal, MD: A Clinician’s Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC

Proton Pump Inhibitor, Antibiotic Exposure Linked to Inferior Durvalumab Outcomes in Unresectable Stage III NSCLC

Rezatapopt Shows Activity in TP53 Y220C–Mutated Advanced Ovarian Cancer

Sugar- vs Artificially Sweetened Beverages and Gastric Cancer Risk

High-Risk ERBB2-Negative Breast Cancer Adding Dual Checkpoint Blockade to Neoadjuvant Chemotherapy